RLYB Rallybio Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: RLYB

Price (delayed)

$16.96

Market cap

$90.07M

P/E Ratio

2.11

Dividend/share

N/A

EPS

$8.05

Enterprise value

-$2.78M

?
Relative Growth: Rel. Growth: 35
Relative Strength: Rel. Strength: 98
Relative Valuation: Rel. Valuation: 78
Relative Profitability: Rel. Profitability: 94
Highlights
The quick ratio has soared by 187% YoY and by 130% from the previous quarter
The equity has surged by 106% year-on-year and by 88% since the previous quarter
Rallybio's gross profit has decreased by 25% from the previous quarter and by 15% YoY
RLYB's revenue is down by 25% from the previous quarter and by 15% YoY
Sector: Healthcare
Industry: Biotechnology
Website: https://www.rallybio.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of RLYB

RLYB stock price

How has the Rallybio stock price performed over time
Intraday
2.23%
1 week
4.76%
1 month
6.73%
1 year
296.26%
YTD
208.93%
QTD
6%

Financial performance

How have Rallybio's revenue and profit performed over time
Revenue
$646,000
Gross profit
$646,000
Operating income
-$27.72M
Net income
$45.55M
Gross margin
100%
Net margin
7,051.2%
RLYB's operating income is up by 36% year-on-year and by 14% since the previous quarter
Rallybio's gross profit has decreased by 25% from the previous quarter and by 15% YoY
RLYB's revenue is down by 25% from the previous quarter and by 15% YoY
Rallybio's operating margin has increased by 25% YoY but it has decreased by 15% from the previous quarter

Price vs fundamentals

How does RLYB's price correlate with its fundamentals

Growth

What is Rallybio's growth rate over time

Valuation

What is Rallybio stock price valuation
P/E
2.11
P/B
0.95
P/S
149.62
EV/EBIT
-0.06
EV/EBITDA
-0.06
EV/Sales
-4.31
The equity has surged by 106% year-on-year and by 88% since the previous quarter
RLYB's price to book (P/B) is 36% higher than its last 4 quarters average of 0.7 but 21% lower than its 5-year quarterly average of 1.2
The stock's price to sales (P/S) is 122% more than its last 4 quarters average of 67.5
RLYB's revenue is down by 25% from the previous quarter and by 15% YoY

Efficiency

How efficient is Rallybio business performance
Rallybio's return on assets has surged by 199% YoY
RLYB's return on equity has surged by 196% year-on-year

Dividends

What is RLYB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RLYB.

Financial health

How did Rallybio financials performed over time
The quick ratio has soared by 187% YoY and by 130% from the previous quarter
The current ratio has surged by 173% year-on-year and by 111% since the previous quarter
RLYB's debt is 100% smaller than its equity
The equity has surged by 106% year-on-year and by 88% since the previous quarter
RLYB's debt has dropped by 100% since the previous quarter and by 100% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.